Zevra Therapeutics Expands Executive Leadership Team - Seite 2

“I am pleased with the opportunity to join the Zevra team during this exciting time of growth for the company,” said Alison Peters. “As Zevra expands its footprint, I plan to leverage my expertise in talent acquisition and retention, as well as executive advisement and employee engagement, to promote a positive and effective company culture.”

Ms. Peters brings more than 20 years of experience in human capital management at biopharmaceutical and medtech companies. Ms. Peters was previously the Chief People Officer and Head of Corporate Communications at Scipher Medicine, a mid-sized precision medicine company, where she played a key role in shaping a culture of high performance through various talent management initiatives. Prior to that, she was the Human Capital Practice Lead at Dominis Group, a human capital and finance consulting firm, where she provided executive coaching on culture, performance, and change management. She previously served as Senior Director of Talent Management at Serica Technologies and VP of Human Resources at Quantia MD, leading HR services and ensuring talent acquisition and retention at each company. Earlier in her career, Ms. Peters worked in Talent Acquisitions and HR for PCI Corporation, Etex Corporation, Akamai Technologies, GTE Internetworking, and Fidelity Investments.

Inducement Awards

On June 21, 2024, the Compensation Committee of Zevra’s Board of Directors granted (i) to Mr. Thompson an inducement equity award consisting of a grant of 200,000 restricted stock units of Zevra’s common stock, vesting over three years, with 33 1/3% vesting on the first anniversary of Mr. Thompson’s start date, and the remainder vesting in two equal annual installments thereafter; (ii) to Ms. Peters an inducement equity award consisting of a grant of 150,000 restricted stock units of Zevra’s common stock, vesting over three years, with 33 1/3% vesting on the first anniversary of Ms. Peters’ start date, and the remainder vesting in two equal annual installments thereafter; and (iii) to three (3) individuals inducement equity awards consisting of restricted stock units to purchase an aggregate of 9,700 shares of Zevra’s common stock, vesting over three years, with 33 1/3% vesting on the first anniversary of each person’s respective start date, and the remainder vesting in two equal annual installments thereafter. The inducement awards were granted under the Zevra Therapeutics, Inc. 2023 Employment Inducement Award Plan (as amended and/or restated, the Inducement Award Plan) and, in each case, an award agreement thereunder.